Cowen analyst Joshua Jennings reiterated an Outperform rating and $8.50 price target on Histogenics Corp. (NASDAQ: HSGX) saying they would ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE